TSN 0.00% 1.0¢ the sustainable nutrition group ltd

Puma and ACL, page-2

  1. 136 Posts.
    lightbulb Created with Sketch. 17
    And Tewk, with those sort of numbers you'd have to think someone would swallow up ACL at some stage if the Phase III results 'exceeds the efficacy of Erbitux in combination with FOLFIRI.' The numbers you've provided would be impossible for a large pharma to ignore, let alone the other potential Hyact applications. Do you think a Nasdaq listing would benefit/be possible, prior to any potential takeover?
 
watchlist Created with Sketch. Add TSN (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.